Caribou Biosciences | LinkedIn (original) (raw)

Biotechnology Research

Berkeley, CA 33,349 followers

Clinical-stage biopharmaceutical company developing transformative therapies to treat devastating human diseases

About us

Caribou Biosciences is a leading clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. Our next-generation genome-editing technology enables superior precision to develop cell therapies that are armored to potentially improve activity against diseases. We believe the future of cell therapy is off-the-shelf, and we are advancing our pipeline of off-the-shelf, or allogeneic, cell therapies from our CAR-T cell therapy platform as readily available treatments for patients with hematologic malignancies and autoimmune diseases.

Industry

Biotechnology Research

Company size

51-200 employees

Headquarters

Berkeley, CA

Type

Public Company

Founded

2012

Specialties

Next-generation CRISPR genome editing, allogeneic CAR-T cell therapies, oncology, and autoimmune

Locations

Employees at Caribou Biosciences

Updates

Join now to see what you are missing

Join now

Similar pages

Browse jobs

Funding